HCPLive

HCPLive HCPLive.com is your one-stop shop for healthcare news, medical conference coverage, and more. Clinical News for Connected Physicians

That's a wrap on a successful Revolutionizing Atopic Derm (RAD) Virtual conference! Thank you to our sponsors for making...
12/08/2024

That's a wrap on a successful Revolutionizing Atopic Derm (RAD) Virtual conference! Thank you to our sponsors for making this year’s virtual event possible! We’re already counting down the days until !

Happening now! Join the live stream to learn about the latest advances in atopic dermatitis. We’ll focus on patient-cent...
12/08/2024

Happening now! Join the live stream to learn about the latest advances in atopic dermatitis. We’ll focus on patient-centered conversations and late-breaking research in this free, virtual, CME/CE event. Join here: https://bit.ly/3ZIpwhl

Check out the latest installment in our   series from NeurologyLive! Learn more about the evolving role of AI in  :
12/05/2024

Check out the latest installment in our series from NeurologyLive!

Learn more about the evolving role of AI in :

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

From 2018-2021, teletherapy boosted use among socioeconomically advantaged adults, yet older, rural, publicly insured, a...
12/05/2024

From 2018-2021, teletherapy boosted use among socioeconomically advantaged adults, yet older, rural, publicly insured, and lower-income groups saw little change.

Read more about the study:

A study revealed that people who are older, uneducated, unemployed, below the poverty line, publicly insured, rural, and male did not increase in psychotherapy use from 2018 to 2021.

12/04/2024

Join our live upcoming broadcast to listen to Dr. Patel, Dr. Weber, and Dr. Bloch discuss a new treatment option for adult patients with difficult to manage hypertension. This expert-led presentation will provide an in-depth discussion about unmet needs in hypertension. See full Prescribing Information including BOXED Warning bit.ly/3AYfsbC, and Medication Guide bit.ly/4g3sSSw Register now bit.ly/3Z7LDgL

SURMOUNT-5 trial data indicates tirzepatide provided greater weight loss than semaglutide at 72 weeks.
12/04/2024

SURMOUNT-5 trial data indicates tirzepatide provided greater weight loss than semaglutide at 72 weeks.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

Hear from Marcelo Kugelmas, MD, about findings from a posthoc analysis of the phase 3 ELATIVE study suggesting elafibran...
11/30/2024

Hear from Marcelo Kugelmas, MD, about findings from a posthoc analysis of the phase 3 ELATIVE study suggesting elafibranor (Iqirvo) does not impact markers of renal function.

Kugelmas reviews findings from a secondary analysis of the phase 3 ELATIVE trial suggesting elafibranor is associated with stable kidney function.

💡 Ketamine shows promise for PTSD & OCD treatment!A systematic review highlights its potential but notes limited RCTs. I...
11/29/2024

💡 Ketamine shows promise for PTSD & OCD treatment!

A systematic review highlights its potential but notes limited RCTs. Investigators urge more research on long-term safety & repeat infusions.

🔗 Read more:

A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.

Use of a novel quality index called the Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) may help improve   manag...
11/28/2024

Use of a novel quality index called the Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) may help improve management and reduce associated hospitalizations.

Learn more:

The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.

We want to extend our heartfelt thanks to the healthcare professionals, patients, and communities that inspire us every ...
11/28/2024

We want to extend our heartfelt thanks to the healthcare professionals, patients, and communities that inspire us every day. Wishing you a joyful and restful Thanksgiving surrounded by loved ones.

Thank you for being part of the HCPLive® community!

Can antipsychotics increase mortality risk in schizophrenia? A new study reveals:• High doses of antipsychotics and benz...
11/27/2024

Can antipsychotics increase mortality risk in schizophrenia? A new study reveals:
• High doses of antipsychotics and benzodiazepines: ↑ mortality risk
• High-dose antidepressants: ↓ mortality risk

Immortal time bias plays a critical role in interpreting results.

Learn more:

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.

The   has accepted Alnylam's sNDA for vutrisiran for the treatment of ATTR-CM. A PDUFA target date of March 23, 2025, wa...
11/27/2024

The has accepted Alnylam's sNDA for vutrisiran for the treatment of ATTR-CM. A PDUFA target date of March 23, 2025, was set after the company used a Priority Review voucher.

Read:

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

Tauseef Ali, MD explores the design and outcomes of a JAK Inhibitor’s Phase 3 Crohn’s Disease Program, showing its effic...
11/26/2024

Tauseef Ali, MD explores the design and outcomes of a JAK Inhibitor’s Phase 3 Crohn’s Disease Program, showing its efficacy across symptomatic and objective endpoints. Check out our iPub Clinical Perspectives in IBD: A JAK Inhibitor in Crohn’s Disease. Watch now. bit.ly/4dcKhWS

Emapalumab may improve outcomes in patients with MAS whose disease didn’t respond to steroid therapy and mitigate the ne...
11/26/2024

Emapalumab may improve outcomes in patients with MAS whose disease didn’t respond to steroid therapy and mitigate the need for more toxic therapies.

Watch Dr. Alexei Grom discuss the study in-depth during now:

Emapalumab may improve outcomes in patients with MAS whose disease didn’t respond to steroid therapy and mitigate the need for more toxic therapies.

Topline results from the LUNA Phase 2 trial and 4-year follow-up of the OPTIC first-in-human trial supported the long-te...
11/26/2024

Topline results from the LUNA Phase 2 trial and 4-year follow-up of the OPTIC first-in-human trial supported the long-term potential of intravitreal Ixo-vec gene therapy for patients with .



Read more:

New 52-week LUNA and 4-year OPTIC data demonstrate Ixo-vec’s potential to reduce injection burden, maintain vision, and achieve lifelong benefits for wet AMD.

Address

2 Clarke Drive
Cranbury, NJ
08512

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 8:30am - 5:30pm

Alerts

Be the first to know and let us send you an email when HCPLive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to HCPLive:

Videos

Share